Oncolytics Biotech Inc T.ONC

ONCY's pelareorep involves direct dendritic cell activation

[Noteable]

Reovirus is a multipotent immune agent with oncolytic properties that has demonstrated clinical efficacy in early phase trials in metastatic KRAS mutant colorectal cancer. Its mechanisms of anti-tumor action involve direct dendritic cell activation, by production of proinflammatory cytokines, dendritic cell mediated NK cell activation, which lead to exocytosis of perforin/granzyme and Fas-associated death domain, and activation of T-cells.

- So Yeon Kim1 , Radhashree Maitra2 , Sanjay Goel1,

1Montefiore Medical Center, 1695 Eastchester Road, Bronx, New York 10461, USA; 2Department of Biology, Yeshiva University, 500 West 185th Street, New York 10033, USA; 3Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, New York

https://e-century.us/files/ajtr/13/12/ajtr0136713.pdf

[Noteable]

Dendritic cells act like the generals of the immune system waking up other immune cells such as T cells and telling them what to attack and the weapons to use. However, cancer cells are very good at hiding from the immune system. By combining pelareorep with immune checkpoint inhibitors, the cancers become visible to the immune system and the reovirus activated dendritic cells go to work and